860 related articles for article (PubMed ID: 23396206)
1. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
[TBL] [Abstract][Full Text] [Related]
2. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Cripe TP; Ngo MC; Geller JI; Louis CU; Currier MA; Racadio JM; Towbin AJ; Rooney CM; Pelusio A; Moon A; Hwang TH; Burke JM; Bell JC; Kirn DH; Breitbach CJ
Mol Ther; 2015 Mar; 23(3):602-8. PubMed ID: 25531693
[TBL] [Abstract][Full Text] [Related]
4. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Heo J; Breitbach CJ; Moon A; Kim CW; Patt R; Kim MK; Lee YK; Oh SY; Woo HY; Parato K; Rintoul J; Falls T; Hickman T; Rhee BG; Bell JC; Kirn DH; Hwang TH
Mol Ther; 2011 Jun; 19(6):1170-9. PubMed ID: 21427706
[TBL] [Abstract][Full Text] [Related]
5. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.
Liu TC; Hwang T; Park BH; Bell J; Kirn DH
Mol Ther; 2008 Sep; 16(9):1637-42. PubMed ID: 18628758
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
7. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
8. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
Breitbach CJ; Bell JC; Hwang TH; Kirn DH; Burke J
Oncolytic Virother; 2015; 4():25-31. PubMed ID: 27512667
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
Breitbach CJ; Moon A; Burke J; Hwang TH; Kirn DH
Methods Mol Biol; 2015; 1317():343-57. PubMed ID: 26072416
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
11. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
Kim JH; Oh JY; Park BH; Lee DE; Kim JS; Park HE; Roh MS; Je JE; Yoon JH; Thorne SH; Kirn D; Hwang TH
Mol Ther; 2006 Sep; 14(3):361-70. PubMed ID: 16905462
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Breitbach CJ; Arulanandam R; De Silva N; Thorne SH; Patt R; Daneshmand M; Moon A; Ilkow C; Burke J; Hwang TH; Heo J; Cho M; Chen H; Angarita FA; Addison C; McCart JA; Bell JC; Kirn DH
Cancer Res; 2013 Feb; 73(4):1265-75. PubMed ID: 23393196
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.
Lun X; Chan J; Zhou H; Sun B; Kelly JJ; Stechishin OO; Bell JC; Parato K; Hu K; Vaillant D; Wang J; Liu TC; Breitbach C; Kirn D; Senger DL; Forsyth PA
Mol Ther; 2010 Nov; 18(11):1927-36. PubMed ID: 20808290
[TBL] [Abstract][Full Text] [Related]
15. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
[TBL] [Abstract][Full Text] [Related]
16. Exploring the role of oncolytic viruses in hepatobiliary cancers.
Tenneti P; Borad MJ; Babiker HM
Immunotherapy; 2018 Aug; 10(11):971-986. PubMed ID: 29900755
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic vaccinia virus for the treatment of cancer.
Guse K; Cerullo V; Hemminki A
Expert Opin Biol Ther; 2011 May; 11(5):595-608. PubMed ID: 21338330
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
Samson A; West EJ; Carmichael J; Scott KJ; Turnbull S; Kuszlewicz B; Dave RV; Peckham-Cooper A; Tidswell E; Kingston J; Johnpulle M; da Silva B; Jennings VA; Bendjama K; Stojkowitz N; Lusky M; Prasad KR; Toogood GJ; Auer R; Bell J; Twelves CJ; Harrington KJ; Vile RG; Pandha H; Errington-Mais F; Ralph C; Newton DJ; Anthoney A; Melcher AA; Collinson F
Cancer Immunol Res; 2022 Jun; 10(6):745-756. PubMed ID: 35439304
[TBL] [Abstract][Full Text] [Related]
20. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE; Ilett EJ; Melcher AA
Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
